The evolving knowledge of the role of BoNT in inhibiting neurogenic inflammation, mainly by impeding nerve-derived release of CGRP and SP, has contributed to its ‘off label’ use for the management of various inflammatory skin disorders, including psoriasis, rosacea [10], atopic dermatitis [11], alopecia [12,13,14], and many other dermatological conditions [15,16,17]. Here, CALCA is linked to psoriasis.